Literature DB >> 16939393

Role of IGF-I signaling in regulating osteoclastogenesis.

Yongmei Wang1, Shigeki Nishida, Hashem Z Elalieh, Roger K Long, Bernard P Halloran, Daniel D Bikle.   

Abstract

UNLABELLED: We showed that IGF-I deficiency impaired osteoclastogenesis directly and/or indirectly by altering the interaction between stromal/osteoblastic cells and osteoclast precursors, reducing RANKL and M-CSF production. These changes lead to impaired bone resorption, resulting in high BV/TV in IGF-I null mice.
INTRODUCTION: Although IGF-I has been clearly identified as an important growth factor in regulating osteoblast function, information regarding its role in osteoclastogenesis is limited. Our study was designed to analyze the role of IGF-I in modulating osteoclastogenesis using IGF-I knockout mice (IGF-I(-/-)).
MATERIALS AND METHODS: Trabecular bone volume (BV/TV), osteoclast number, and morphology of IGF-I(-/-) or wildtype mice (IGF-I(+/+)) were evaluated in vivo by histological analysis. Osteoclast precursors from these mice were cultured in the presence of RANKL and macrophage-colony stimulating factor (M-CSF) or co-cultured with stromal/osteoblastic cells from either genotype. Osteoclast formation was assessed by measuring the number of multinucleated TRACP+ cells and pit formation. The mRNA levels of osteoclast regulation markers were determined by quantitative RT-PCR.
RESULTS: In vivo, IGF-I(-/-) mice have higher BV/TV and fewer (76% of IGF-I(+/+)) and smaller osteoclasts with fewer nuclei. In vitro, in the presence of RANKL and M-CSF, osteoclast number (55% of IGF-I(+/+)) and resorptive area (30% of IGF-I(+/+)) in osteoclast precursor cultures from IGF-I(-/-) mice were significantly fewer and smaller than that from the IGF-I(+/+) mice. IGF-I (10 ng/ml) increased the size, number (2.6-fold), and function (resorptive area, 2.7-fold) of osteoclasts in cultures from IGF-I(+/+) mice, with weaker stimulation in cultures from IGF-I(-/-) mice. In co-cultures of IGF-I(-/-) osteoblasts with IGF-I(+/+) osteoclast precursors, or IGF-I(+/+) osteoblasts with IGF-I(-/-) osteoclast precursors, the number of osteoclasts formed was only 11% and 48%, respectively, of that from co-cultures of IGF-I(+/+) osteoblasts and IGF-I(+/+) osteoclast precursors. In the long bones from IGF-I(-/-) mice, mRNA levels of RANKL, RANK, M-CSF, and c-fms were 55%, 33%, 60%, and 35% of that from IGF-I(+/+) mice, respectively.
CONCLUSIONS: Our results indicate that IGF-I regulates osteoclastogenesis by promoting their differentiation. IGF-I is required for maintaining the normal interaction between the osteoblast and osteoclast to support osteoclastogenesis through its regulation of RANKL and RANK expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939393     DOI: 10.1359/jbmr.060610

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  74 in total

Review 1.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

2.  Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover.

Authors:  Melita M Dvorak-Ewell; Tsui-Hua Chen; Nathan Liang; Caitlin Garvey; Betty Liu; Chialing Tu; Wenhan Chang; Daniel D Bikle; Dolores M Shoback
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

Review 3.  Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development.

Authors:  Yongmei Wang; Daniel D Bikle; Wenhan Chang
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

Review 4.  Emerging therapeutic opportunities for skeletal restoration.

Authors:  Masanobu Kawai; Ulrike I Mödder; Sundeep Khosla; Clifford J Rosen
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

5.  Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.

Authors:  Jerome Moreaux; Dirk Hose; Alboukadel Kassambara; Thierry Reme; Philippe Moine; Guilhem Requirand; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

6.  Conditional deletion of insulin-like growth factor-I in collagen type 1alpha2-expressing cells results in postnatal lethality and a dramatic reduction in bone accretion.

Authors:  Kristen E Govoni; Jon E Wergedal; Lore Florin; Peter Angel; David J Baylink; Subburaman Mohan
Journal:  Endocrinology       Date:  2007-08-23       Impact factor: 4.736

7.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

8.  Joint loading-driven bone formation and signaling pathways predicted from genome-wide expression profiles.

Authors:  Ping Zhang; Charles H Turner; Hiroki Yokota
Journal:  Bone       Date:  2009-02-07       Impact factor: 4.398

Review 9.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

10.  PI3K/AKT pathway involvement in the osteogenic effects of osteoclast culture supernatants on preosteoblast cells.

Authors:  Li-Li Chen; Mei Huang; Jing-Yi Tan; Xiao-Tao Chen; Li-Hong Lei; Yan-Min Wu; Di-Ya Zhang
Journal:  Tissue Eng Part A       Date:  2013-05-30       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.